Doses of GBR12909 that suppress cocaine self-administration in non- human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans

Synapse

Volumn 32, Issue 1, 1999, Pages 44-50

  Villemagne, Victor L ^a   Rothman, Richard B ^c   Yokoi, Fuji ^a   Rice, Kenner C ^b   Matecka, Dorota ^b   Dannals, Robert F ^a   Wong, Dean F ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Dopamine transporter; Non human primate; PET; Transporter occupancy

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARBON 11; DOPAMINE TRANSPORTER; VANOXERINE;

ANIMAL EXPERIMENT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LIMBIC SYSTEM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RHESUS MONKEY;

ANIMALS; CARBON RADIOISOTOPES; CARRIER PROTEINS; COCAINE; DEPRESSION, CHEMICAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSIONS, INTRAVENOUS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PAPIO; PIPERAZINES; SELF ADMINISTRATION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033044162     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199904)32:1<44::AID-SYN6>3.0.CO;2-9     Document Type: Article

References (67)

1. Bartzokis G, Beckson M, Newton T, Mandelkern M, Mintz J, Foster JA, Ling W, Bridge P. 1997. Selegeline alters cocaine-induced changes in brain metabolism and euphoria. Am Coll Neuropsychopharmacol 118:110.
2. Baumann MH, Char GU, de Costa BR, Rice KC, Rothman RB. 1994. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther 271:1216-1222.
3. Baxter BL, Gluckman MI, Stein L, Scerni RA. 1974. Self-injection of apomorphine in the rat: positive reinforcement by a dopamine receptor stimulant. Pharmacol Biochem Behav 2:387-391.
4. Benowitz NL. 1993. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 72:3-12.
5. Brady K, Anton R, Ballenger JC, Lydiard RB, Adinoff B, Selander J. 1990. Cocaine abuse among schizophrenic patients. Am J Psychiat 147:1164-1167.
6. Brauer LH, de Wit H. 1996. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry 39:26-32.
7. Brauer LH, de Wit H. 1997. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacol Biochem Behav 56:265-272.
8. Brauer LH, Goudie AJ, de Wit H. 1997. Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology 130:2-13.
9. Bunt G, Galanter M, Lifshutz H, Castaneda R. 1990. Cocaine/"crack" dependence among psychiatric inpatients. Am J Psychiat 147:1542-1546.
10. Dannals RF, Neumeyer JL, Milius RA, Ravert HT, Wilson AA, Wagner HN Jr. 1993. Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET: 2b-Carbomethoxy-3b-(4-fluorophenyl)-[N-11C-methyl]tropane ([11C]CFT or [11C]WIN-35,428). J Label Compd Radiopharm 33:147-153.
11. Das G. 1993. Cocaine abuse in North America: a milestone in history. J Clin Pharmacol 33:296-310.
12. De La Garza R, Johanson CE. 1982. Effects of haloperidol and physostigmine on self-administration of local anesthetics. Pharmacol Biochem Behav 17:1295-1299.
13. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. 1991. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiat 148:224-230.
14. Dworkin SI, Peris J, Yasuda RP, Philpott K, Zahniser NR. 1988. Neurobehavioral pharmacology of cocaine. NIDA Res Monogr 88:185-198.
15. Dworkin SI, Lambert P, Sizemore GM, Carroll FI, Kuhar MJ. 1998. RTI-113 Administration reduces cocaine self-administration at high occupancy of dopamine transporter. Synapse 30:49-55.
16. Ettenberg A, Pettit HO, Bloom FE, Koob GF. 1982. Heroin and cocaine self-administration in rats: mediation by separate neural systems. Psychopharmacology 78:204-209.
17. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. 1995. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15:19S-23S.
18. Glowa JR, Wojnicki FHE, Matecka D, Bacher JJ, Mansbach RS, Balster RL, Rice KC. 1995a. Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: I. Dependence on unit dose of cocaine. Exp Clin Psychopharmacol 3:219-231.
19. Glowa JR, Wojnicki FHE, Matecka D, Rice KC, Rothman RB. 1995b. Effects of dopamine reuptake inhibitors on food and cocaine maintained responding. II: Comparisons with other drugs and repeated administrations. Exp Clin Psychopharmacol 3:231-239.
20. Goyer PF, Berridge MS, Morris ED, Semple WE, Compton-Toth BA, Schulz SC, Wong DF, Miraldi F, Meltzer HY. 1996. PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med 37:1122-1127.
21. 2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 17:175-185.
22. Haberny KA, Walsh SL, Ginn DH, Wilkins JN, Garner JE, Setoda D, Bigelow GE. 1995. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Dependence 39:55-62.
23. Heinonen EH, Lammintausta R. 1991. A review of the pharmacology of selegiline. Acta Neurol Scand Suppl 136:44-59.
24. Johanson CE, Fischman MW. 1989. The pharmacology of cocaine related to its abuse. Pharmacol Rev 41:3-52.
25. Johanson CE, Kandal CE, Bonese KF. 1976. The effects of perphenazine on self-administration behavior. Pharmacol Biochem Behav 4:427-433.
26. Knoll J. 1983. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl 95:57-80.
27. Koob GF, Le HT, Creese I. 1987. D-1 receptor antagonist SCH23390 increases cocaine self-administration in the rat. Neurosci Lett 79:315-321.
28. Koob GF, Vaccarion FJ, Amalric M. Bloom FE. 1987. Positive reinforcement properties of drugs: search for neural substrates. In: Engel J, Oreland L, editors. Brain reward systems and abuse. New York: Raven Press, p 35-50.
29. Kuhar MJ, Sanchez-Roa PM, Wong DF, Dannals RF, Grigoriadis DE, Lew R, Milberger M. 1990. Dopamine transporter: biochemistry, pharmacology and imaging. Eur Neurol 30 (Suppl 1): 15-20.
30. Kuhar MJ, Ritz MC, Boja JW. 1991. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14:299-302.
31. 3H]Cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 251:131-141.
32. Malison RT, Wright S, Sanacora G, Potenza M, Mechanic K, Haroon E, Carpenter L, Pelton G, Self D, Kosten T, Krystal J, Nestler EJ. 1997. Reductions in cocaine-induced craving following the selective D1 dopamine receptor agonist ABT-431 in human cocaine abusers. Am Coll Neuropsychopharmacol 208:200 (abstract).
33. Musto DF. 1992. Cocaine's history, especially the American experience. Ciba Found Symp 166:7-14.
34. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 1993. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 110:265-272.
35. Ohuoha DC, Maxwell JA, Thomson LE, Cadet JL, Rothman RB. 1997. Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. J Subst Abuse Treat 14:249-258.
36. Preston KL, Sullivan JT, Strain EC, Bigelow GE. 1992. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther 262:279-291.
37. Price LH, Pelton GH, Cappiello A, McDougle CJ, Malison RT, Jatlow P, Kosten TR, Heninger GR. 1995. Attenuation of cocaine effects by reserpine in cocaine-dependent humans. Am Coll Neuropsychopharmacol 193:190 (abstract).
38. Price LH, Pelton GH, McDougle CJ, Malison RT, Jatlow P, Carpenter L, Kirwin PD, O'Brien DW, Nadim H, Heninger GR. 1997. Effects of acute pretreatment with risperidone on responses to cocaine in cocaine addicts. Am Coll Neuropsychopharmacol 208:200 (abstract).
39. Risner ME, Silcox DL. 1981. Psychostimulant self-administration by beagle dogs in a progressive-ratio paradigm. Psychopharmacology 75:25-30.
40. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. 1987. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223.
41. Roberts DC, Vickers G. 1984. Atypical neuroleptics increase self-administration of cocaine: an evaluation of a behavioural screen for antipsychotic activity. Psychopharmacology 82:135-139.
42. Roberts DCS, Corcoran ME, Fibiger HC. 1977. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol Biochem Behav 6:615-620.
43. Roberts DCS, Koob GF. 1982. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmentum area in rats. Pharmacol Biochem Behav 17:901-904.
44. Rothman RB. 1990. High affinity dopamine reuptake blockers as potential cocaine antagonists: a strategy for drug development. Life Sci 46:PL17-PL21.
45. Rothman RB. 1994. A review of the effects of dopamimetic agents in humans: implications for medication development. NIDA Res Monogr 145:67-85.
46. Rothman RB, Glowa JR. 1995. A review of the effects of dopaminergic agents on humans, animals and drug seeking behavior, and its implications for medication development: focus on GBR12909. Mol Neurobiol 11:1-19.
47. Rothman RB, Grieg N, Kim A, de Costa BR, Rice KC, Carroll FI, Pert A. 1992. Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacol Biochem Behav 43:1135-1142.
48. Rothman RB, Mele A, Reid AA, Akunne HC, Greig N. Thurkauf A, de Costa BR, Rice KC, Pert A. 1991. GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav 40:387-397.
49. Schneier FR, Siris SG. 1987. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J Nerv Ment Dis 175:641-652.
50. Sevy S, Kay SR, Opler LA, van Praag HM. 1990. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 178:642-648.
51. Skjoldager P, Winger G. Woods JH. 1993. Effects of GBR 12909 and cocaine on cocaine-maintained behavior in rhesus monkeys. Drug Alcohol Depend 33:31-39.
52. Spealman RD, Madras BK, Bergman J. 1989. Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther 251:142-149.
53. Spyraki C, Fibiger HC. 1981. Intravenous self-administration of nomifensine in rats: implications for abuse potential in humans. Science 212:1167-1168.
54. Stine SM, Krystal JH, Petrakis IL, Jatlow PI, Heninger GR, Kosten TR, Charney DS. 1997. Effect of alpha-methyl-para-tyrosine on response to cocaine challenge. Biol Psychiatry 42:181-190.
55. Tanda G, Pontieri FE, Frau R, Di Chiara G. 1997. Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine, Eur J Neurosci 9:2077-2085.
56. Tella SR. 1995. Effects of monoamine reuptake inhibitors on cocaine self-administration in rats. Pharmacol Biochem Behav 51:687-692.
57. Tella SR, Ladenheim B, Andrews AM, Goldberg SR, Cadet JL. 1996. Differential reinforcing effects of cocaine and GBR-12909: biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. J Neurosci 16:7416-7427.
58. Van der Zee P, Koger HS, Gootjes J, Hespe W. 1980. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur J Med Chem 15:363-370.
59. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE. 1997. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827-830.
60. Wilson MC, Schuster CR. 1972. The effects of chlorpromazine on psychomotor stimulant self-administration in the rhesus monkey. Psychopharmacologia 26:115-126.
61. Wilson MC, Schuster CR. 1976. Mazindol self-administration in the rhesus monkey. Pharmacol Biochem Behav 4:207-210.
62. Wise RA. 1984. Neural mechanisms of the reinforcing action of cocaine. NIDA Res Monogr 50:15-33.
63. 11C]WIN 35,428. Synapse 15:130-142.
64. Woods JH, Herling S, Winger G. 1978. Chlorpromazine- and haloperidol-induced changes in some behavioral effects of cocaine and amphetamine. In: Deniker P, Radouco-Thomas C, Villeneuve A, editors. Neuro-psychopharmacology, Proceedings of the Tenth Congress of Collegium International Neuro-Psychopharmacologicum, New York: Pergamon Press, p 1485-1502.
65. Woods JH, Katz JL, Medzihradsky F, Smith CB, Winger GD. 1983. Evaluation of new compounds for opioid activity: 1982 annual report. NIDA Res Monogr 43:457-511.
66. Woolverton WL, Goldberg LI, Ginos JZ. 1984. Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J Pharmacol Exp Ther 230:678-683.
67. Yokel RA, Wise RA. 1978. Amphetamine-type reinforcement by dopaminergic agonists in the rat. Psychopharmacology (Berlin) 58:289-296.